​

Intellia Therapeutics Ownership | Who Owns Intellia Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Intellia Therapeutics Ownership Summary

Intellia Therapeutics is owned by 73.36% institutional investors, 4.51% insiders, and 22.13% retail investors. Ark investment management is the largest institutional shareholder, holding 12.89% of NTLA shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 8.11% of its assets in Intellia Therapeutics shares.

NTLA Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockIntellia Therapeutics73.36%4.51%22.13%
SectorHealthcare Stocks 232.52%10.72%-143.24%
IndustryBiotech Stocks 384.56%10.59%-295.14%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ark investment management14.21M12.89%$127.72M
Vanguard group13.01M11.81%$116.96M
Blackrock9.60M10.05%$214.79M
Blackrock funding, inc. /de10.28M9.33%$92.39M
State street4.97M4.79%$85.85M
Regeneron pharmaceuticals3.70M3.36%$33.29M
Baker bros. advisors lp2.75M2.65%$47.44M
Geode capital management2.70M2.45%$24.24M
Two sigma investments, lp2.45M2.36%$42.30M
Morgan stanley2.33M2.11%$20.93M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Regeneron pharmaceuticals3.70M98.49%$33.29M
Contrarius investment management1.92M2.68%$42.87M
Discovery value fund97.98K2.35%$880.80K
Ark investment management14.21M0.85%$127.72M
Birchview capital, lp60.00K0.78%$1.04M
Orchard capital management82.03K0.64%$737.45K
Himension capital (singapore) pte.565.13K0.60%$9.76M
Iq eq fund management (ireland)731.42K0.45%$6.58M
Baker bros. advisors lp2.75M0.34%$47.44M
Contrarius group714.48K0.31%$6.42M

Top Buyers

HolderShares% AssetsChange
Ark investment management14.21M0.85%2.29M
Vanguard group13.01M0.00%1.97M
Renaissance1.67M0.02%1.02M
Blackrock funding, inc. /de10.28M0.00%1.00M
State street4.97M0.00%931.58K

Top Sellers

HolderShares% AssetsChange
Contrarius group714.48K0.31%-5.18M
Deep track capital, lp---4.95M
Capital investors---3.78M
Morgan stanley2.33M0.00%-3.69M
Goldman sachs group1.46M0.00%-2.82M

New Positions

HolderShares% AssetsChangeValue
Farallon capital management607.20K0.04%607.20K$10.49M
Steadfast capital management lp365.40K0.11%365.40K$6.31M
Wasatch advisors lp313.69K0.02%313.69K$2.82M
Connor, clark & lunn investment management259.71K0.01%259.71K$2.33M
Point72 asset management174.26K0.01%174.26K$3.01M

Sold Out

HolderChange
Dinuzzo private wealth-1.00
Global financial private client-1.00
Activest wealth management-1.00
Jfs wealth advisors-2.00
Richard w. paul & associates-2.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025221-28.25%80,835,304-22.43%730.82%102-32.45%72-10.00%
Sep 30, 20252891.05%103,222,25512.82%991.28%143-2.72%76-8.43%
Jun 30, 2025290-7.05%98,735,343-2.49%950.99%146-0.68%85-10.53%
Mar 31, 20256-98.05%3,804,135-96.17%30.04%3-98.41%1-98.55%
Dec 31, 2024286-2.39%92,252,291-1.01%911.07%17817.11%61-27.38%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
ARK Disruptive Innovation Full Composite8.71M8.11%966.00
ARK Innovation ETF8.28M7.71%61.21K
American Funds SMALLCAP World A3.78M3.65%3.78M
Vanguard US Total Market Shares ETF3.17M3.06%299.88K
Vanguard Total Stock Mkt Idx Inv3.17M2.95%-70.23K
ARK Genomic Revolution ETF2.89M2.69%-10.31K
ARK Genomic Revolution2.88M2.68%-220.20K
Vanguard Small Cap Index2.51M2.34%-16.78K
iShares Russell 2000 ETF2.48M2.31%-
Nikko AM ARK Disruptive Innovation A USD1.76M1.70%-68.46K

Recent Insider Transactions

DateNameRoleActivityValue
Jan 05, 2026LEONARD JOHN M President and CEOSell$314.48K
Jan 05, 2026Schultes Birgit C EVP, Chief Scientific OfficerSell$78.36K
Jan 05, 2026BASTA JAMES EVP, General CounselSell$95.76K
Jan 05, 2026Cohen Fred E-Buy$1.40M
Jan 05, 2026Lebwohl David EVP, Chief Medical OfficerSell$109.63K

Insider Transactions Trends

DateBuySell
2026 Q117
2025 Q4-5
2025 Q314
2025 Q2-2
2025 Q1-11

NTLA Ownership FAQ

Who Owns Intellia Therapeutics?

Intellia Therapeutics shareholders are primarily institutional investors at 73.36%, followed by 4.51% insiders and 22.13% retail investors. The average institutional ownership in Intellia Therapeutics's industry, Biotech Stocks , is 384.56%, which Intellia Therapeutics falls below.

Who owns the most shares of Intellia Therapeutics?

Intellia Therapeutics’s largest shareholders are Ark investment management (14.21M shares, 12.89%), Vanguard group (13.01M shares, 11.81%), and Blackrock (9.6M shares, 10.05%). Together, they hold 34.75% of Intellia Therapeutics’s total shares outstanding.

Does Blackrock own Intellia Therapeutics?

Yes, BlackRock owns 10.05% of Intellia Therapeutics, totaling 9.6M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 214.79M$. In the last quarter, BlackRock increased its holdings by 488.34K shares, a 5.36% change.

Who is Intellia Therapeutics’s biggest shareholder by percentage of total assets invested?

Regeneron pharmaceuticals is Intellia Therapeutics’s biggest shareholder by percentage of total assets invested, with 98.49% of its assets in 3.7M Intellia Therapeutics shares, valued at 33.29M$.

Who is the top mutual fund holder of Intellia Therapeutics shares?

ARK Disruptive Innovation Full Composite is the top mutual fund holder of Intellia Therapeutics shares, with 8.11% of its total shares outstanding invested in 8.71M Intellia Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools